Clinical trial design for new cancer therapies has historically been focused on the tissue of origin of a tumor, but a paper from researchers at Memorial Sloan-Kettering Cancer Center published in Nature Genetics supports a new approach: one based on the genomic signature of a tumor rather than the tissue of origin in the body.
Fuente : http://www.eurekalert.org/pub_releases/2013-09/msc…
Hacer un comentario